Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Complement Therapeutics logo — Developing the next generation of complement medicines

Complement Therapeutics

Developing the next generation of complement medicines

Founded 2020 Germany Germany 36 employees Series A Total: $77.00M Biotechnology

General Information

Company Name Complement Therapeutics
Founded Year 2020
Location Germany Germany
Employees 36
Industries Biotechnology
Funding Stage Series A
Business Model B2B, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Complement Therapeutics. To contact Complement Therapeutics, visit complementtx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Complement Therapeutics compare?

A PDF of Complement Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Complement Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Complement Therapeutics

Complement Therapeutics, founded in 2020, is a biotechnology company dedicated to pioneering the development of the next generation of complement medicines. Headquartered in Germany, this spinout from the University of Manchester focuses on innovative therapeutics for complement-mediated diseases.

Their lead candidate, CTx001, is under evaluation as a gene therapy for Geographic Atrophy (GA), a major cause of blindness among the elderly. With research labs in Stevenage, UK, and subsidiaries in the UK and USA, Complement Therapeutics is strategically positioned for broad international research and development.

In a recent Series A funding round, the company secured €72.00M from prominent investors including BioGeneration Ventures, Forbion, Cambridge Innovation Capital, GIMV, Hadean Partners, Panakes Partners, and Seroba Life Sciences. This investment reflects strong confidence in its potential to address significant unmet clinical needs in the field of biotechnology.

Business keywords: Complement-Mediated Diseases, Gene Therapy, Geographic Atrophy, Dry Age-Related Macular Degeneration, Precision Medicine, Diagnostic Platform, Vision Loss, Retinal Diseases, Complement Cascade, Preclinical Research, Patient Stratification, Efficacy Biomarker, Therapeutic Development

Services & Products

Research and development of complement-related disease therapies
Development of gene and protein-based therapeutic platforms
Mass spectrometry for complement protein measurement

Target Customers

Patients with complement-mediated diseases Individuals with age-related macular degeneration Healthcare providers specializing in ocular and systemic diseases

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €72.00M 7
BioGeneration Ventures Forbion Cambridge Innovation Capital
BioGeneration Ventures, Forbion +5
17 Apr 2023
Seed Round €5.00M 2
BioGeneration Ventures Forbion
BioGeneration Ventures, Forbion
23 Feb 2022
Seed Round Undisclosed 1
BioGeneration Ventures
BioGeneration Ventures
01 Jan 2021

Latest News

View All
The 10 fastest-growing startup teams in the UK — Sifted
The 10 fastest-growing startup teams in the UK
Sifted Jun 10, 2024

Complement Therapeutics Alternatives & Competitors

View All Alternatives
Complement Therapeutics vs
Adverum Biotechnologies
Adverum Biotechnologies United States

We are on a global mission to establish gene therapy as a new standard of care for the leading cause...

Acquired
133 employees
Biotechnology, Health and Wellness
Compare Complement Therapeutics vs Adverum Biotechnologies
Complement Therapeutics vs
EyeBio
EyeBio United Kingdom

Developing a new generation of therapies to protect, restore, and improve vision

Acquired
109 employees
Biotechnology
Compare Complement Therapeutics vs EyeBio
Complement Therapeutics vs
Alumis
Alumis United States

Transforming the lives of patients living with immune-mediated diseases using a precision approach.

Series C
249 employees
Biotechnology, Health Care
Also compare with: Complement Therapeutics vs Alkeus Pharmaceuticals, Inc. Alkeus Pharmaceuticals, Inc. Complement Therapeutics vs Beacon Therapeutics Beacon Therapeutics View all alternatives

FAQ About Complement Therapeutics

Developing the next generation of complement medicines
Complement Therapeutics was founded in 2020.
Complement Therapeutics is headquartered in Germany.
Complement Therapeutics operates in Biotechnology. Its work centres on Complement-Mediated Diseases, Gene Therapy, Geographic Atrophy and Dry Age-Related Macular Degeneration. Its customers include Patients with complement-mediated diseases, Individuals with age-related macular degeneration and Healthcare providers specializing in ocular and systemic diseases.
Complement Therapeutics has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.
Complement Therapeutics has approximately 36 employees.
Complement Therapeutics has completed 3 funding rounds, raising a total of $77.00M. The latest funding stage is Series A.
Complement Therapeutics offers: Research and development of complement-related disease therapies, Development of gene and protein-based therapeutic platforms, Mass spectrometry for complement protein measurement.
Top alternatives and competitors to Complement Therapeutics include Adverum Biotechnologies, EyeBio, Alumis, CiRC Biosciences, Alkeus Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Complement Therapeutics and Adverum Biotechnologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Complement Therapeutics, https://bouncewatch.com/company/complement-therapeutics, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout